

IN THE SPECIFICATION:

Please replace the last paragraph on page 4, extending to the top of page 5 of the application (paragraph [0019] in Pub. No.: US 2002/0147159) with the following amended paragraph:

[0019] Acarbose is an oral ~~alpha-glucoside inhibitor~~ alpha glucosidase inhibitor approved for use in the management of non-insulin-dependent diabetes mellitus (NIDDM). Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates. It is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes. It has not been proven that metabolites have inhibitory activity on oligosaccharide digestion.